No Data
No Data
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
Express News | HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target
Unity Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 422.88% HC Wainwright & Co. → $8 Reiterates Buy → Buy 04/16/2024 422.88% HC Wainwright & Co. $1
Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
PDF Version SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or rever
Express News | Unity Biotechnology Q1 EPS $(0.34) Beats $(0.47) Estimate